TytoCare has closed a $25 million-plus growth round and appointed Adam Pellegrini as Chief Executive Officer, as the company expands its AI-first clinical enablement platform for remote care.

The financing was led by Insight Partners, with participation from existing strategic investors including HOOP, OliveTree, OrbiMed, Qumra Capital and Qualcomm Ventures. The proceeds will support expansion of TytoCare’s AI clinical algorithms pipeline, payer and health system partnerships, and go-to-market activity for chronic and serious disease populations.

This is relevant because telehealth adoption has grown, but many virtual care models still lack diagnostic fidelity. Remote consultations can be limited when clinicians cannot conduct physical examinations or capture reliable clinical-grade data from the home.

TytoCare’s platform combines a handheld remote examination device with FDA-cleared medical devices and FDA-cleared AI-powered Software as a Medical Device algorithms. The system can support remote capture of heart, lung, ear, skin, throat and abdomen data.

The company is positioning the platform for virtual primary care, remote cardiopulmonary monitoring, oncology support and complex chronic disease management. Target areas include congestive heart failure, COPD, post-surgical recovery and oncology treatment monitoring.

The differentiation lies in moving remote care beyond video consultation. By embedding remote examination data and AI-supported outputs into care workflows, TytoCare aims to help clinicians make more confident decisions without requiring every patient to attend an in-person visit.